Ghent University Academic Bibliography

Advanced

Bedside monitoring of anticoagulation in chronic haemodialysis patients treated with tinzaparin

Ruben Pauwels, Katrien Devreese UGent, Wim Van Biesen UGent, Sunny Eloot UGent, Griet Glorieux UGent, Raymond Vanholder UGent and Annemieke Dhondt UGent (2014) NEPHROLOGY DIALYSIS TRANSPLANTATION. 29(5). p.1092-1096
abstract
Background. During haemodialysis, anticoagulants are required to prevent clotting in the extracorporeal circuit. Low-molecular weight heparins (LMWH) are frequently used because of the ease of a single injection at the start of dialysis. Disadvantages of LMWH include the lack of a reliable bedside assay for measuring their anticoagulant effect. Methods. We investigated a bedside test for LMWH activity. The relationship between anti-Xa (chromogenic assay) and Hemonox point-of-care assay was evaluated in 21 dialysis patients (12 men and 9 women) with a median age of 71 years, receiving tinzaparin at the start of a haemodiafiltration session. Results. At the start, before tinzaparin administration, median (interquartile ranges) of Hemonox values were 74 (67–82) s. Thirty minutes after tinzaparin administration, Hemonox values were increased to 496 (360–736) s, followed by a decrease to 149 (135–301) s after 120 min, 102 (97–144) s after 180 min and 92 (83–100) s after 240 min. Corresponding anti-Xa activities were 0 (0–0), 1.12 (0.9–1.29), 0.74 (0.57–0.96), 0.47 (0.31–0.7) and 0.31(0.16–0.49) IU/mL. Hemonox values showed an exponential relation to anti-Xa levels. Interchangeability of tests was shown by Bland–Altman plot. Conclusion. Point-of-care Hemonox test is a valuable bedside method for monitoring anti-Xa activity in dialysis patients anticoagulated with tinzaparin.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
tinzaparin, Hemonox, lowmolecular weight heparin, anti-Xa activity, haemodialysis, MOLECULAR-WEIGHT HEPARIN, ENOXAPARIN, POINT
journal title
NEPHROLOGY DIALYSIS TRANSPLANTATION
Nephrol. Dial. Transplant.
volume
29
issue
5
pages
1092 - 1096
Web of Science type
Article
Web of Science id
000336093900023
JCR category
UROLOGY & NEPHROLOGY
JCR impact factor
3.577 (2014)
JCR rank
12/78 (2014)
JCR quartile
1 (2014)
ISSN
0931-0509
DOI
10.1093/ndt/gft508
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
4301496
handle
http://hdl.handle.net/1854/LU-4301496
date created
2014-02-24 15:21:04
date last changed
2016-12-19 15:39:38
@article{4301496,
  abstract     = {Background. During haemodialysis, anticoagulants are required to prevent clotting in the extracorporeal circuit. Low-molecular weight heparins (LMWH) are frequently used because of the ease of a single injection at the start of dialysis. Disadvantages of LMWH include the lack of a reliable bedside assay for measuring their anticoagulant effect.
Methods. We investigated a bedside test for LMWH activity. The relationship between anti-Xa (chromogenic assay) and Hemonox point-of-care assay was evaluated in 21 dialysis patients (12 men and 9 women) with a median age of 71 years, receiving tinzaparin at the start of a haemodiafiltration session.
Results. At the start, before tinzaparin administration, median (interquartile ranges) of Hemonox values were 74 (67--82) s. Thirty minutes after tinzaparin administration, Hemonox values were increased to 496 (360--736) s, followed by a decrease to 149 (135--301) s after 120 min, 102 (97--144) s after 180 min and 92 (83--100) s after 240 min. Corresponding anti-Xa activities were 0 (0--0), 1.12 (0.9--1.29), 0.74 (0.57--0.96), 0.47 (0.31--0.7) and 0.31(0.16--0.49) IU/mL. Hemonox values showed an exponential relation to anti-Xa levels. Interchangeability of tests was shown by Bland--Altman plot.
Conclusion. Point-of-care Hemonox test is a valuable bedside method for monitoring anti-Xa activity in dialysis patients anticoagulated with tinzaparin.},
  author       = {Pauwels, Ruben and Devreese, Katrien and Van Biesen, Wim and Eloot, Sunny and Glorieux, Griet and Vanholder, Raymond and Dhondt, Annemieke},
  issn         = {0931-0509},
  journal      = {NEPHROLOGY DIALYSIS TRANSPLANTATION},
  keyword      = {tinzaparin,Hemonox,lowmolecular weight heparin,anti-Xa activity,haemodialysis,MOLECULAR-WEIGHT HEPARIN,ENOXAPARIN,POINT},
  language     = {eng},
  number       = {5},
  pages        = {1092--1096},
  title        = {Bedside monitoring of anticoagulation in chronic haemodialysis patients treated with tinzaparin},
  url          = {http://dx.doi.org/10.1093/ndt/gft508},
  volume       = {29},
  year         = {2014},
}

Chicago
Pauwels, Ruben, Katrien Devreese, Wim Van Biesen, Sunny Eloot, Griet Glorieux, Raymond Vanholder, and Annemieke Dhondt. 2014. “Bedside Monitoring of Anticoagulation in Chronic Haemodialysis Patients Treated with Tinzaparin.” Nephrology Dialysis Transplantation 29 (5): 1092–1096.
APA
Pauwels, Ruben, Devreese, K., Van Biesen, W., Eloot, S., Glorieux, G., Vanholder, R., & Dhondt, A. (2014). Bedside monitoring of anticoagulation in chronic haemodialysis patients treated with tinzaparin. NEPHROLOGY DIALYSIS TRANSPLANTATION, 29(5), 1092–1096.
Vancouver
1.
Pauwels R, Devreese K, Van Biesen W, Eloot S, Glorieux G, Vanholder R, et al. Bedside monitoring of anticoagulation in chronic haemodialysis patients treated with tinzaparin. NEPHROLOGY DIALYSIS TRANSPLANTATION. 2014;29(5):1092–6.
MLA
Pauwels, Ruben, Katrien Devreese, Wim Van Biesen, et al. “Bedside Monitoring of Anticoagulation in Chronic Haemodialysis Patients Treated with Tinzaparin.” NEPHROLOGY DIALYSIS TRANSPLANTATION 29.5 (2014): 1092–1096. Print.